Akebia Therapeutics (AKBA) Earnings Analysis
Akebia Therapeutics (AKBA) next reports earnings on 2026-08-06, consensus EPS -0.03 USD. Last quarter (2026-05-07) it missed with EPS -0.03 USD vs -0.01 USD est (-200%). It has beaten estimates in 3/7 recent quarters (43%). Trailing P/E -16.34.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does AKBA next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.03 USD |
| Revenue estimate | 0.05B |
AKBA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.03 USD | -0.01 USD | -200% | Miss |
| 2026-02-26 | -0.05 USD | -0.03 USD | -66.7% | Miss |
| 2025-11-10 | 0.00197 USD | -0.06 USD | +103.3% | Beat |
| 2025-08-07 | 0.00091 USD | -0.02 USD | +104.6% | Beat |
| 2025-03-13 | -0.1 USD | -0.05 USD | -100% | Miss |
| 2024-11-07 | -0.1 USD | -0.05 USD | -100% | Miss |
| 2024-08-08 | -0.04 USD | -0.06 USD | +33.3% | Beat |
Beat rate: 3/7 (43%) over reported quarters with consensus data.
AKBA valuation and analyst view
| Trailing P/E | -16.34 |
|---|---|
| Trailing EPS | -0.07681 USD |
| Price / book | 12.29 |
| Dividend yield | 0.00% |
| Market cap | 0.34B |
| Analyst consensus | Buy (7 buy / 3 hold / 1 sell) |
| Avg price target | 4 USD |
Related research pages
Frequently asked questions
When is Akebia Therapeutics (AKBA)'s next earnings date?
Akebia Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.03 USD and revenue estimate of 0.05B.
Did AKBA beat earnings last quarter?
In its 2026-05-07 report, AKBA posted EPS of -0.03 USD versus a -0.01 USD estimate — a miss of 200%.
What is AKBA's earnings track record?
Over the last 7 reported quarters with consensus data, AKBA beat estimates 3 times (43%).
What is AKBA's current P/E ratio and EPS?
AKBA trades at a trailing P/E of -16.34 on trailing EPS of -0.0768067749035183 USD.
What do analysts rate AKBA?
Analyst consensus is "Buy" across 11 ratings (0 strong buy, 7 buy, 3 hold, 1 sell, 0 strong sell). Average 12-month price target: 4 USD.